Ramucirumab is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells.
- Mechanism
- Curator reviewed
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.
- Primary indication
- Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy.Curator reviewed · 9 structured indications
- Formula / weight
- C6374H9864N1692O1996S46 · 143600.0 Da
- First approval
- Canada, 2015 · United States, 2014 · European Union, 2020
- Code names
- 1121B · IMC-1121B · LY-3009806
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Ramucirumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account